

Posting Date: 16th December 2025

Tender Reference: UHS/LAB/TENDER/033/2025

Tender Expiry Date: 22nd January 2026

Title: Molecular Outsource Laboratory Test

Dear Valued Vendors

University Hospital Sharjah (UHS) has decided to invite vendors for a Tender. You, as a vendor are requested to participate in the tender process by submitting your offer for one or more of the items described in attached technical indicative document.

The Tenderer should comply with the following terms & conditions:

1. All the prices should be presented in UAE Dirham.
2. The price quoted is inclusive of:
 - a. A detailed description of Molecular Oncology tests offered (**Listed Appendix 1**).
 - b. Price lists for each test.
 - c. Turnaround time (TAT) for each test.
 - d. Sample requirements for each test.
 - e. Logistics and transport arrangements for sample collection and delivery.
3. The financial offer should be on your company letterhead containing the authorized signatory and may please be sent to the attention of the Director of Finance, **University Hospital Sharjah, PO Box 72772, Sharjah in a sealed document**.
4. All sample pick-up should be made for the requested quantity in full, from our Laboratory Department, or designated area of sample collection, located in UHS vicinity or as specified on the Contract. Failure to comply with the agreed pick-up may result in penalties or contract termination, as per the Agreement Terms and Conditions.
5. As a part of the Tender document, the Vendors are requested to provide their valid Trade License, Name, and Designation of the Managing Director/General Manager/Sr. Manager have the authority to bind their company for the business relationship. Also, is required the authorization letter/Agency certificate confirming that the vendor is legalized to supply the items on behalf of the manufacturer/principal company. As well as the following documents:
 - a) Valid Trade License
 - b) Updated Company Profile
 - c) Tax Registration Certificate (TRN)
 - d) Full Company Address & Contact Details
 - e) Memorandum of Association (MOA) and Power of Attorney (POA) for authorized signatory (if applicable)

- f) An official Authorization Letter/Agency Certificate, confirming the vendor's legal authorization to supply the specified items on behalf of the manufacturer or principal company.
- g) Any additional approvals or compliance documents mandated by government authorities for the supply of the specified equipment.
- h) Non-Liability Letter and Legal Clearance Confirmation.
- i) Insurance Policies (General Liability, Professional Indemnity, etc.).
- j) Declaration of No Ongoing Legal Disputes.
- k) Vendor Code of Conduct Acknowledgment.

6. Standard payment terms are 90 days from the date of sample collection of all the items ordered or as specifically agreed in writing by the University Hospital Sharjah.
7. Any delays sample collection or delay in releasing of result as per agreed TAT or non-conformance may result in the termination of contract and/or imposition of penalty for delayed as per Agreement terms and conditions. **A performance bond may be required to ensure commitment to the agreed timelines and quality standards.**
8. The proposal shall be evaluated & approved by UHS's technical team before confirmation. Once the agreement is signed off, the performance of the test shall have to correspond to the same method, quality, specification, and source as originally agreed and any deviations shall be considered a contractual breach.
9. The specified brand and manufacturer related to the performance of the contract must remain unchanged throughout the contract period unless otherwise approved by UHS Laboratory in writing.
10. UHS will be constantly evaluating the compliance of Contracted Terms and consistency in the performance of the contact. The supplier is required to submit regular progress reports at agreed intervals detailing progress, challenges, and actions to address any delays or issues. Should Vendors not meet the requirements of UHS, therefore UHS reserves the right to terminate the contract if the vendor is not able to rectify during the time allotted by UHS's representative. Purchase Contact details (landline, mobile, emails) of the authorized representatives should be mentioned.
11. **Tenders should be submitted in two sealed envelopes and submitted to the Administration Office Finance Department- UHS:**
 - a. **The Technical Specification details (PLEASE DO NOT INDICATE ANY FINANCIAL VALUE IN THIS).** If requested for additional clarifications and details these need to be submitted to **(Administration Office Finance Department- UHS).**
 - i. The technical offer should conform with test specification as per the tender requirement.
 - ii. Technical offer (hard copy and soft copy).
 - iii. Reference Hospital
 - b. **The Financial Offer** addressed to UHS's Director of Finance, with **tender reference**.

All above documents should be submitted before the tender expiry date, all documents submitted after the expiry date will not be accepted.

12. UHS shall have no obligation to accept any tender proposal submitted by any vendor. UHS may at its sole discretion and without providing any reason, accept or reject any or all proposals, in whole or in part. Such rejection shall not give rise to any claim, liability, or cause of action of any kind by the vendor against UHS.
13. Submission of a tender proposal shall not create and agreement, legal or other relationship between the vendor and UHS. No vendor shall acquire any rights, interests, or claims against UHS by submitting a proposal, participating in the tender process or relying on any communications related to the tender.
14. In the event UHS accepts a tender proposal of a vendor, the parties agree any such tender award will be subject to a Services Agreement and separate agreement outlining the specific terms and conditions of the project and services agreed.
15. All costs, expenses or losses incurred by the vendor in connection with the preparation, submission of presentation of its proposal shall be borne sole by the vendor. UHS shall have no liability, under any circumstances to reimburse, compensate or indemnify the vendor whether in part or in whole for such costs or expenses.
16. The vendors acknowledge and agree that they have not relied on any statement, representation, warranty, or promise made by UHS, whether oral or written, in preparing their tender proposal and all decisions and judgements regarding the submission of their proposal are made at their own discretion and risk.
17. UHS may at any time without liability, amend, suspend, or withdraw the tender invitation in whole or in part. UHS may also request additional information, clarifications or documents from any vendor and may reject any proposal that is incomplete, unclear or does not comply with the tender requirements as outlined in this document.
18. Quality, Price, and sale services are combined parameters for tender evaluation. Once a vendor has been selected, a negotiation period will follow to allow both parties to review the agreement terms thoroughly. This will ensure that all deliverables, KPIs, and expectations are clearly outlined before the final agreement is signed.
19. Vendors must submit a risk management plan, identifying potential risks to the project, such as security and confidentiality breaches, system failures, and disruptions to delivery schedules. Vendors should outline how they intend to address these risks, including their disaster recovery and business continuity plans.
20. Vendors are encouraged to adhere to ethical practices and sustainability standards in their operations. This includes providing energy-efficient equipment and adopting environmentally friendly practices in their supply chain and delivery.
21. The Vendor, its employees, its subsidiaries, and everyone who has a direct or indirect relationship with implementing and securing the works and Services included within the scope of this tender, shall be obligated to inform UHS and disclose in writing any case of conflict of interest or any private interest that has arisen, will arise, or may arise. For any transaction related to the activities of UHS, in accordance with UHS policies.
22. The vendor, its employees, and subsidiaries shall be obligated to maintain confidentiality of any data, drawings, documents, or information related to the tender - written or oral. Vendors must ensure that any data shared is protected by encryption standards and secure transfer protocols. Additionally, vendors are required to notify UHS of any data breaches immediately. Compliance with relevant data privacy regulations (e.g., GDPR, UAE Data Protection Law) is mandatory. This includes all dealings, affairs, or secrets related to UHS they may have encountered during

the tender process. Vendors shall not be allowed to disclose any information related to the tender through any media outlet without obtaining prior written approval from UHS.

23. The copyright, rights and ownership of any documents, materials and information submitted by UHS within this tender is owned by UHS, and accordingly, these documents and materials may not be copied, in whole or in part, or reproduced, distributed, made available to any third party, or used without obtaining prior written approval from UHS. If the vendor develops any custom software or systems for UHS as part of this tender, UHS will retain ownership of the intellectual property or have clear licensing terms for its continued use. All documents submitted by the UHS in connection with the request for proposals shall be returned upon request without any copies being retained by the bidder or any other person.
24. The vendors shall indemnify, defend and hold harmless UHS, its officers, employees and agents from and against any and all claims, liabilities, losses, damage costs, or expenses arising out of or in connection with:
 - a. the vendors participation in the tender process
 - b. any errors, omissions, misrepresentations or inaccuracies in the proposal
 - c. any breach of the vendors' obligations under this tender invitation
25. To the maximum extent permitted by law, UHS expressly excludes any liability for:
 - a. Any direct, indirect, incidental, consequential or special losses
 - b. Loss of profits, revenue, goodwill or business opportunities
 - c. Any claims by third parties arising from a vendor's proposal
 - d. Any loss or damage caused by errors, omissions or delays in the tender process
26. This tender invitation and all matters relating to it shall be governed by any construed in accordance with the laws of the United Arab Emirates. The competent courts of Sharjah, United Arab Emirates shall have exclusive jurisdiction over any disputes arising from or in connection with this tender.
27. This document and clauses therein constitute the entire understanding between UHS and any vendor regarding liability, proposal submission, and the tender process. No other communication, agreement or understanding, whether oral or written shall be deemed to modify, supersede, or expand these clauses.

University Hospital Sharjah

Appendix 1- Molecular Outsource Laboratory Test:

No.	Test Category	Sample Type	Analysis Type	Gene / Marker Coverage	Key Purpose
1	Comprehensive molecular profiling	Tissue or blood	Somatic ± Germline	1021 genes (DNA & RNA), ± PD-L1	Guides targeted therapy and immunotherapy decisions through detailed tumor molecular characterization
2	Hereditary cancer risk assessment	Blood	Germline	Multiple cancer-associated genes	Identifies inherited mutations linked to breast and other cancers; supports risk assessment, prevention, and surveillance
3	Multi-gene tumor profiling	Tissue (FFPE)	Somatic	Multiple genes relevant to colon and lung cancer	Supports personalized treatment planning by analyzing tumor biology
4	Hereditary cancer panel	Blood	Germline	52 genes	Comprehensive NGS analysis of genes associated with hereditary cancer syndromes
5	Comprehensive genomic profiling (tissue)	Tissue (FFPE)	Somatic	1021 genes (DNA & RNA) + PD-L1	In-depth tumor profiling for precision oncology
6	Comprehensive genomic profiling (liquid)	Blood	Somatic & Germline	1021 genes (DNA & RNA) + germline mutations	Non-invasive tumor and inherited mutation detection
7	Comprehensive genomic profiling (tissue + liquid)	Tissue + blood	Somatic & Germline	1021 genes (DNA & RNA) + PD-L1 + germline mutations	Combined approach for maximal mutation detection
8	Colon cancer molecular panel	Tissue (FFPE)	Somatic	24 genes + 6 fusions + MSI	Mutation and MSI detection to guide colon cancer treatment
9	Lung cancer molecular panel	Tissue (FFPE)	Somatic	24 genes + 6 fusions	Mutation and fusion detection for lung cancer therapy selection
10	Sarcoma fusion analysis	Tissue	Somatic	58 gene rearrangements	Detection of sarcoma-associated gene fusions
11	BRCA analysis (tumor)	Tissue	Somatic	BRCA1 & BRCA2 (full sequencing)	Identifies somatic BRCA mutations in breast cancer
12	BRCA analysis (inherited)	Blood	Germline	BRCA1 & BRCA2 (full sequencing)	Detects inherited BRCA mutations
13	Microsatellite instability analysis	Tissue	Somatic	MSI markers (NGS-based)	Identifies MSI status for immunotherapy decision-making